Freight Surge and Gulf Tensions Threaten India’s Pharma Exports; Industry Flags Potential ?5,000-Crore Impact

Escalating freight costs and geopolitical tensions in West Asia are disrupting shipping routes, raising concerns about delays and rising logistics costs for India’s pharmaceutical exports

News

Rising freight costs and geopolitical tensions in West Asia are emerging as significant challenges for India’s pharmaceutical exporters, with industry estimates indicating that shipments worth up to ₹5,000 crore could be affected if disruptions continue in the coming weeks.

According to industry bodies and export officials, volatility in global freight markets and regional security tensions have led to higher shipping costs and uncertainty in cargo movement, particularly affecting routes connected to the Gulf and West Asian markets.

India’s pharmaceutical exports—valued at over $30 billion annually—depend heavily on stable global logistics networks. Disruptions in maritime routes and surging freight charges are therefore raising concerns among exporters about delivery schedules and operational costs.

Middle East tensions disrupt key shipping routes

The current disruption has been linked to rising tensions in the Gulf region, which have increased risks along key maritime and air cargo corridors used for trade between Asia and the Middle East.

Industry estimates indicate that freight costs for shipments of pharmaceutical ingredients and bulk drugs have risen sharply in recent weeks. Container freight rates for certain routes have reportedly doubled, while shipping lines have introduced additional surcharges for cargo moving through sensitive regional routes.

Logistics providers have also tightened shipping schedules, and some cargo operators have reportedly reduced or temporarily halted shipments to specific destinations due to security concerns and higher operational risks.

The Middle East and GCC countries account for around 5–6% of India’s pharmaceutical exports, while several regional ports also serve as important transit hubs for shipments destined for other global markets.

Supply chain pressures across imports and exports

Industry observers say the freight surge could impact both sides of India’s pharmaceutical supply chain.

India’s pharmaceutical industry relies significantly on imports of active pharmaceutical ingredients (APIs), intermediates, and key raw materials, many of which are sourced from China and other Asian markets. Higher freight costs could therefore increase input costs for manufacturers.

At the same time, finished pharmaceutical products exported from India to West Asia and neighbouring regions may face higher transportation costs and longer transit times, potentially affecting delivery timelines and export margins.

Exporters monitor shipment schedules amid uncertainty

Exporters are closely monitoring the situation as logistics volatility increases. Industry officials say shipping delays and limited cargo availability have already begun affecting shipment planning.

The situation is particularly sensitive as companies typically accelerate shipments toward the end of the financial year in March, making reliable freight availability crucial during this period.

Restrictions on certain air routes in the region have also reduced alternative transport options that exporters sometimes rely on for urgent pharmaceutical consignments.

Companies adjust supply strategies

To mitigate logistics risks, some pharmaceutical companies have started adjusting their supply strategies by increasing buffer inventories and extending production planning cycles.

Industry experts note that companies across the global pharmaceutical supply chain have been building larger safety stocks following previous disruptions in shipping routes over the past few years.

This approach helps companies absorb short-term logistical disruptions, though sustained freight volatility could still raise operational costs for exporters.

Implications for India’s global pharma trade

India remains one of the world’s largest suppliers of generic medicines and vaccines, serving markets across more than 200 countries and territories.

According to government data, India’s pharmaceutical exports reached $30.47 billion in FY2024–25, underlining the country’s role in global medicine supply chains.

However, prolonged disruptions across shipping routes in the Gulf and Red Sea region could increase logistics costs, delay temperature-sensitive pharmaceutical shipments, and compress margins for exporters.

Industry observers say companies are currently monitoring developments closely while attempting to maintain stable supply commitments to international markets.